Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Henan Normal Univ. STING compound 3S-12: sourced facts only. name: "The representative compound 3S-12 exhibited potent STING inhibitory activity with IC50 of 0.124 μM for m-STING and 0.533 μM for h-STING." [PMID:41066957]; target: "The representative compound 3S-12 exhibited potent STING inhibitory activity with IC50 of 0.124 μM for m-STING and 0.533 μM for h-STING." [PMID:41066957]; developer: "Collaborative Innovation Center of Henan Province for Green Manufacturing of Fine Chemicals, Key Laboratory of Green Chemical Media and Reactions, Ministry of Education, Henan Key Laboratory of Organic Functional Molecule and Drug Innovation, School of Chemistry and Chemical Engineering, Henan Normal University, Xinxiang, Henan 453007, PR China." [PMID:41066957]; stage: "In the cisplatin-induced acute kidney injury model, 3S-12 significantly alleviated tissue injury and inflammation." [PMID:41066957]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Henan Normal Univ. STING compound 3S-12.